Colonic mucosa-associated lymphoid tissue lymphoma: a case series. Issue 3 (23rd February 2020)

• Record Type: Journal Article
• Authors: Tannoury, Jenny; Amiot, Aurélien; Lemonnier, François; Dupuis, Jehan; Gagnière, Charlotte; Belhadj, Karim; Bras, Fabien Le; Sobhani, Iradj; Haioun, Corinne; Copie-Bergman, Christiane; Lévy, Michaël
• Is Part Of: Leukemia & lymphoma. Volume 61:Issue 3(2020)
• Page Start: 582
• Page End: 587
• Publication Date: 2020-02-23
• Subjects: Lymphoma and Hodgkin disease -- antibody-based immunotherapy -- chemotherapeutic approaches; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2019.1686501
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Primary colonic mucosa-associated lymphoid tissue (MALT) lymphoma accounts for less than 0.5% of all colon cancers. We report 9 cases of colonic MALT lymphomas (median follow up: 9 [IQR 1–26] years). The disease was multi-focal in 4 patients: the most frequent sites were the cecum in 4 and the rectum in 3 patients. The main endoscopic finding was a polypoid lesion. The treatment modalities were rituximab +/− an alkylating agent ( n = 5), an alkylating agent alone ( n = 2), surgical resection ( n = 1), and endoscopic resection ( n = 1). Remission was achieved in 8 cases. Three patients relapsed, and 2 were re-treated. At the end of the study period, 67% of the patients were in remission. All patients were symptom-free. This current series of colonic MALT lymphomas shows the indolent nature of the disease, which may be treated with various modalities.